132 related articles for article (PubMed ID: 8049495)
1. Prostaglandins in the treatment of cancer.
Sasaki H; Fukushima M
Anticancer Drugs; 1994 Apr; 5(2):131-8. PubMed ID: 8049495
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.
Kikuchi Y; Kita T; Miyauchi M; Hirata J; Sasa H; Nagata I; Fukushima M
J Cancer Res Clin Oncol; 1992; 118(6):453-7. PubMed ID: 1618893
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of delta 7-prostaglandin A1 and delta 12-prostaglandin J2 in vitro and in vivo.
Kato T; Fukushima M; Kurozumi S; Noyori R
Cancer Res; 1986 Jul; 46(7):3538-42. PubMed ID: 3708585
[TBL] [Abstract][Full Text] [Related]
4. Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins.
Kikuchi Y; Kita T; Hirata J; Kuki E; Nagata I; Fukushima M
Int J Immunopharmacol; 1992 Jan; 14(1):105-10. PubMed ID: 1582730
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin.
Fukushima S; Kishimoto S; Takeuchi Y; Fukushima M
Adv Drug Deliv Rev; 2000 Dec; 45(1):65-75. PubMed ID: 11104898
[TBL] [Abstract][Full Text] [Related]
6. Use of lipid microspheres as a drug carrier for antitumour drugs.
Mizushima Y; Shoji Y; Kato T; Fukushima M; Kurozumi S
J Pharm Pharmacol; 1986 Feb; 38(2):132-4. PubMed ID: 2870158
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the proliferation of transformed epidermal cells in culture by various prostaglandins.
Ikai K; Ujihara M; Kashihara M; Fukushima M
J Invest Dermatol; 1987 Jul; 89(1):69-72. PubMed ID: 2439606
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of topoisomerases by antitumor prostaglandins.
Suzuki K; Shono F; Uyeda M
Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of cyclopentenone prostaglandins in early HTLV-1 infection is independent of IL-2 and is associated with HSP70 induction.
D'Onofrio C; Franzese O; De Marco A; Bonmassar E; Amici C
Leukemia; 1994 Jun; 8(6):1045-56. PubMed ID: 7516027
[TBL] [Abstract][Full Text] [Related]
10. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets.
Straus DS; Glass CK
Med Res Rev; 2001 May; 21(3):185-210. PubMed ID: 11301410
[TBL] [Abstract][Full Text] [Related]
11. Human ovarian cancer cell lines resistant to cisplatin, doxorubicin, and L-phenylalanine mustard are sensitive to delta 7-prostaglandin A1 and delta 12-prostaglandin J2.
Sasaki H; Takada K; Terashima Y; Ekimoto H; Takahashi K; Tsuruo T; Fukushima M
Gynecol Oncol; 1991 Apr; 41(1):36-40. PubMed ID: 2026357
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory properties of antitumor prostaglandins against topoisomerases.
Suzuki K; Uyeda M
Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human melanoma growth by prostaglandin A, D, and J analogues.
Bregman MD; Funk C; Fukushima M
Cancer Res; 1986 Jun; 46(6):2740-4. PubMed ID: 3698005
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-deoxy-Delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826).
Fukushima S; Takeuchi Y; Kishimoto S; Yamashita S; Uetsuki K; Shirakawa S; Suzuki M; Furuta K; Noyori R; Sasaki H; Kikuchi Y; Kita T; Yamori T; Sawada J; Kojima M; Hazato A; Kurozumi S; Fukushima M
Anticancer Drugs; 2001 Mar; 12(3):221-34. PubMed ID: 11290870
[TBL] [Abstract][Full Text] [Related]
15. Functional antagonism between IL-2 and PGA1 or PGJ2 in the control of proliferation of human cord blood-derived mononuclear cells.
Franzese O; Bonmassar E; Marcucci A; D'Onofrio C
Int J Immunopharmacol; 1996 Nov; 18(11):609-22. PubMed ID: 9089005
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle effects of prostaglandins A1, A2, and D2 in human and murine melanoma cells in culture.
Bhuyan BK; Adams EG; Badiner GJ; Li LH; Barden K
Cancer Res; 1986 Apr; 46(4 Pt 1):1688-93. PubMed ID: 3456266
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.
ElAttar TM; Virji AS
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):461-5. PubMed ID: 9223658
[TBL] [Abstract][Full Text] [Related]
18. Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition.
Narumiya S; Fukushima M
J Pharmacol Exp Ther; 1986 Nov; 239(2):500-5. PubMed ID: 3772804
[TBL] [Abstract][Full Text] [Related]
19. Preferential binding of growth inhibitory prostaglandins by the target protein of a carcinogen.
Khan SH; Sorof S
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9401-5. PubMed ID: 2251282
[TBL] [Abstract][Full Text] [Related]
20. Comparative anti-viral and anti-proliferative activity of PGA1 and PGJ2 against HTLV-I-infected MT-2 cells.
D'Onofrio C; Amici C; Puglianiello A; Faraoni I; Lanzilli G; Santoro MG; Bonmassar E
Int J Cancer; 1992 May; 51(3):481-8. PubMed ID: 1592539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
